Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms|Breast Tumors|Cancer|Locally Recurrent and Metastatic Breast Cancer|Metastases|Metastatic Cancer|Oncology|Solid Tumors|Tumors
Interventions: DRUG: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|DRUG: AMG 386 30 mg/kg, Capecitabine and Lapatinib|DRUG: AMG 386 10 mgkg, Paclitaxel and Trastuzumab|DRUG: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsor: Amgen